Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: InfanDx, Illumina, Artemis DNA, Lifespin, Labcorp, More

NEW YORK – German diagnostics firm InfanDx said this week that it has set up US operations, incorporating a wholly owned subsidiary based in Boston. The company’s US operations will focus on a clinical trial for its HypoxE test to generate data for submission to the US Food and Drug Administration, InfanDx said in a statement. The firm is currently planning the clinical trial protocol and intends to request a pre-submission meeting with the FDA. It has engaged research organization Global BioClinical to help with the trial.

Illumina said this week that it has opened an 11,000-square-foot "Solution Center" in São Paulo to showcase its sequencing and microarray technologies and to offer training to customers and partners in Brazil and Latin America.

Diagnostic testing firm Artemis DNA said this week that it is opening its first international location in Ho Chi Minh City, Vietnam. Starting this month, the Irvine, California-based firm will offer its genetic testing technology and portfolio as well as a cancer screening test named Trucheck Pragma in Vietnam. The blood-based screening test was developed by cancer research company Datar Cancer Genetics for the early detection of prostate, breast, ovary, lung, stomach, colon, and pancreatic cancers. Artemis will exclusively distribute Trucheck Pragma in Vietnam. Other terms of the deal were not disclosed.

Premier Medical Laboratory Services said this week that it has received accreditation from the College of American Pathologists. The designation verifies that the lab meets all required standards from CLIA, the US Food and Drug Administration, and the Occupational Safety and Health Administration, the Greenville, South Carolina-based firm said. PMLS provides molecular diagnostics services for cardiovascular disease, women's health, pharmacogenomics, COVID-19, and other indications.

German metabolomics firm Lifespin said this week that it has opened a US location to accelerate its access to the US clinical and research markets as it expands its business and R&D operations in the US. Based initially in Boston, the US operation will be led by Trevor Hawkins, a member of the company’s board of directors.

Caris Life Sciences said this week that the University of Kentucky Markey Cancer Center has joined Caris' Precision Oncology Alliance, a worldwide network of cancer centers that collaborate to advance precision oncology and biomarker-driven research. The network now includes 62 cancer centers and academic institutions. Its members have early access to Caris' database and artificial intelligence platform to establish evidence-based standards for cancer profiling and molecular testing in oncology.

Laboratory Corporation of America last week declared a cash dividend of $.72 per share of common stock, payable on June 9 to stockholders of record as of the close of business on May 19.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.